In:
Open Forum Infectious Diseases, Oxford University Press (OUP)
Abstract:
Depressive symptoms are prevalent among people who inject drugs (PWID) and people living with hepatitis C virus (HCV). We examined changes in depressive symptoms among HCV-infected PWID following direct-acting antiviral treatments to evaluate whether these changes differed by history of depressive symptoms, substance use, or HCV treatment outcome. Methods We conducted a secondary analysis of the HERO Study (NCT02824640), a pragmatic randomized clinical trial among PWID to test the effectiveness of HCV care models. Depressive symptoms (primary outcome) were measured using the Patient Health Questionnaire (PHQ-9) at baseline, end of treatment (EOT), and at follow-up 12 and 24 weeks after EOT. Sustained virologic response (SVR) was defined as undetectable HCV RNA at ≥12 weeks following EOT. Baseline drug use was defined as having a positive urine screening test for amphetamine, methamphetamine, benzodiazepine, cocaine, cannabis, opiate, or oxycodone. Results The sample (N=498) was 72.3% male, 64.2% White and on average 43.9 years old. In patients who achieved SVR [F(3,432)=4.58, p=.004] and those with drug use at baseline [F(3,478)=5.11, p & lt;.01], PHQ-9 scores significantly declined over time, with scores lower at EOT and both follow-ups as compared to the baseline. Mean PHQ-9 scores at EOT and follow-ups were significantly lower than at baseline except for those with none or mild depression at baseline. Conclusions This study showed that HCV treatment in PWID is associated with sustained declines in depression up to 24 weeks post-treatment among those who achieve SVR, and that drug use does not interfere with improvement in depressive symptoms.
Type of Medium:
Online Resource
ISSN:
2328-8957
DOI:
10.1093/ofid/ofad498
Language:
English
Publisher:
Oxford University Press (OUP)
Publication Date:
2023
detail.hit.zdb_id:
2757767-3
Bookmarklink